向类固醇受体协活性剂-1在瘤发生中的多方面的治疗价值
Qiang Chen1,2, Peng Guo3,4, Yilin Hong4
1Zhejiang Key Laboratory of Pathophysiology, Department of Biochemistry and Molecular Biology, Health Science Center, Ningbo University, Ningbo, Zhejiang, 315211, China. chenqiang1@nbu.edu.cn.
Cell & bioscience
|March 30, 2024
概括
类固醇受体协活性剂-1 (SRC-1) 通过改变基因表达和染色质可访问性来驱动癌症的进展. 虽然抑制SRC-1显示出抗瘤潜力,但其用于癌症治疗的临床应用仍然有限.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 类固醇受体协活性剂-1 (SRC-1,也称为NCOA1) 是一个关键的转录协活性剂.
- SRC-1在各种癌症的瘤发生中发挥着重要作用,包括乳腺癌,前列腺癌和胃肠道癌.
- 它的功能超出了类固醇激素产生的组织,表明它具有更广泛的致癌作用.
研究的目的:
- 审查SRC-1在癌症进展中的致癌作用.
- 确定SRC-1的主要合作者和调节基因.
- 绘制SRC-1促进原发性瘤进展的机制.
主要方法:
- 对SRC-1的致癌功能证据的文献综述.
- 分析SRC-1与转录因子和调节基因的相互作用.
- 参与SRC-1-介导基因转录和染色质重塑的分子机制的映射.
主要成果:
- SRC-1通过增强染色质可访问性和形成转录复合体来促进基因转录.
- SRC-1促进了多种癌症类型的进展.
- 新出现的证据表明,与雄激素受体 (AR) 或雌激素受体 (ER) 独立的新型联合激活模式.
结论:
- 通过多种分子机制,SRC-1是瘤进展的关键促进者.
- 药理上抑制SRC-1是一种潜在的治疗策略,但目前临床应用有限.
- 需要进一步的研究,以充分阐明SRC-1的多器官致癌作用,并开发有效的治疗干预措施.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Co-activators and Co-repressors
7.3K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.3K
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


